摘要
目的观察比较多西他赛联合顺铂(TP方案)与吉西他滨联合顺铂(GP方案)治疗晚期非小细胞肺癌(NSCLC)的疗效和毒性反应。方法97例晚期NSCLC患者随机分为TP组51例和GP组46例,化疗两个周期后,对两组的临床疗效和毒性反应进行评价。结果TP组及GP组有效率分别为54.9%和41.3%,(P<0.05),中位疾病进展时间分别为9个月及4个月,中位生存期分别为15个月及9个月。毒性反应以骨髓抑制和胃肠道反应为主。结论TP方案治疗NSCLC近期疗效高于GP方案(P<0.05),毒性反应可以耐受。
Objective To compare the efficacy and toxicity of docetaxel combined with cisplatin,（TP regimen）against gemcitabine plus cisplatin（GP regimen）in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods A total of 97 advanced NSCLC patients were randomized to the two regimens. 51 patients were treated with TP regimen and 46 patients were treated with GP regimen. And all completed at least two cycles. Results The effective rates of TP group and GP group were 54. 9% and 41. 3% ,respectively（P 0. 05）. The times to disease progress were 9 months and 9 months,respectively. The median survival times were 15months and 8 months. The main toxicity was bone marrow suppression and the gastrointestinal reactions. Conclusion TP short-term efficacy in the treatment of NSCLC higher than the GP program,toxicity can be tolerated.
出处
《中国现代药物应用》
2010年第7期26-28,共3页
Chinese Journal of Modern Drug Application
关键词
多西他赛
吉西他滨
顺铂
非小细胞肺癌
化疗
Docetaxel
Gemcitabine
Cisplatin
Non-small cell lung cancer
Chemotherapy
